[Skip to Content]
[Skip to Content Landing]
October 1981

γ-Type Endorphins and Schizophrenia

Author Affiliations

Department of Psychiatry
Rudolf Magnus Institute for Pharmacology
Department of Psychiatry State University Nicolaas Beetsstraat 24 Utrecht, the Netherlands

Arch Gen Psychiatry. 1981;38(10):1182. doi:10.1001/archpsyc.1981.01780350116012

To the Editor.—  In reference to the article "Des-Tyrosine-γ-Endorphin [DTγE] Administration in Chronic Schizophrenics: A Preliminary Report" by Tamminga et al (Archives 1981;38:167-168), we agree with the conclusion of the authors that DTγE does not have an antipsychotic activity in chronic (residual) schizophrenics. However, we found an antipsychotic action in more than 50% of our patients, which may be related to the type of schizophrenic illness and the history of our patients.Based on animal experiments, de Wied et al1 have postulated that DTγE or a closely related neuropeptide may be an endogenous entity with antipsychotic activity and with a profile more specific than the currently used neuroleptic drugs. The results of our first two clinical studies with DTγE in 13 patients with chronic relapsing schizophrenia and schizoaffective psychoses have been published in this journal.2 Since that time, we have performed a third clinical trial including ten schizophrenic

First Page Preview View Large
First page PDF preview
First page PDF preview